Harmful Patent Strategies
EU Commission imposes heavy fine of €462.6 million on Teva for abuse of dominant market position.
Teva
Teva Intends to Divest API Business
Israeli generics manufacturer Teva Pharmaceuticals intends to divest its active pharmaceutical ingredient (API) business, Teva API (TAPI). A standalone business unit of Teva, TAPI supplies APIs to over 1,000 customers worldwide and has approximately 4,300 employees worldwide.
Sanofi Enters into Partnerships with Janssen and Teva
Sanofi has entered into an agreement with Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, to develop and commercialize the vaccine candidate for extraintestinal pathogenic E. coli (9-valent) developed by Janssen, a potential first-in-class product currently in Phase 3.
Flamma Invests $200 Million to Expand CDMO Capabilities
Italian CDMO Flamma Group intends to invest $200 million over the next three years to expand its capabilities to meet growing market demand.
